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Rational or rationed medicine? The promise of genetics for improved clinical practice
Robin Fears, Derek Roberts, George Poste A recent BMJ editorial highlighted the challenges and the opportunities for improving the quality of health care that are afforded by advances in genomics and molecular medicine. 1 It also emphasised that the NHS must develop a coherent strategy to realise the substantial benefits that new technologies can deliver. We applaud this recommendation and the concluding sentiment that "at a time of uncertainty about future potential, the NHS must anticipate innovation, not block it." A BMJ editorial published a year earlier had also drawn attention to the urgency in meeting the challenge of defining future service needs by orchestrating optimum relations between laboratory, clinic, and society.
2 Much has been written since then about the likely future impact of genetics on clinical care, the potential models for service provision, 3 and the broader ethical, legal, and social issues relating to the use of genetic information for non-medical purposes. However, there seems to be little tangible progress in the capacity of the NHS to anticipate and respond to the accelerating momentum of technological change.
We believe that a pluralistic approach, with commitment to a new public-private partnership in strategic thinking and policy development might help to inform NHS priorities and preparedness. The BMJ editorial described the United Kingdom's aspiration to become the "Genome Valley" of Europe by building on a strong bioscience base for generating health and wealth, 1 and it is understandable that the Silicon Valley experience in the United States should be chosen as a model in developing this. However, we need to understand and analyse the factors contributing to the success of Silicon Valley in order to determine whether they can be generalised to medical research and development and the NHS. Foremost in the evolution of the microelectronic and computer industries in California was the large public procurement market created by the US Department of Defence's demand for silicon integrated circuits. By analogy, without a market "pull" created by the NHS acting as an informed and innovative customer, it will be difficult to capitalise on our bioscience excellence and make the genome valley aspiration a reality.
The scientific promise
The impact of genetics on medicine may prove to be greater than that of any previous scientific advance. 4 The contribution of molecular genetics in describing a new taxonomy for common diseases and in identifying new targets for treatment has been described elsewhere. 4 5 In addition to inspiring rational drug design, genomics will substantially redefine clinical practice by creating new categories of diagnostic tests and ways of identifying individual predisposition to disease. 4 5 The initial impact is already being seen in clinical practice (for example, with the introduction of testing for factor V Leiden as a risk factor for recurrent thromboembolic events 6 ), and a range of risk factors will be available for clinical characterisation within the next five years. The evolution of pharmacogenetic tools to characterise individual responsiveness to drugs or the risk of adverse drug reactions, or both, is of major importance. This will provide a powerful impetus for rational therapy and for reducing unnecessary costs by targeting medicines at those patients who will benefit. The identification of a pharmacogenetic association between the 5-lipoxygenase promoter genotype and the response to asthma treatment is a recent example of a development that has potential relevance for tailoring treatment to the patient. 7 Profiling of patients' risks may help reduce the number of admissions to hospital that arise because of adverse drug reactions and interactions. These admissions are currently estimated at more than two million each year in the United States. 8 A further practical example of what may be gained by research is the understanding of the association between polymorphisms in cytochrome P450 CYP 2C9 with the dose requirement for warfarin and the risk of bleeding complications. 9 At present, the NHS focuses exclusively-and reactively-on existing disease. The impetus that will catalyse change to a public health model of service, with increasing emphasis on disease prediction and prevention, and greater efficiency through targeting scarce resources (figure), will also challenge the pharmaceutical industry to adjust its sights from today's mass markets to diverse clinical micromarkets. 10 The opportunities and constraints facing companies that wish to capitalise on research and development
Summary points
Genomics research and the use of genetic information will transform performance in the health service and the pharmaceutical industry Since cost benefit implications for health care and health gain will be complex, pilot work is needed to explore options Current mechanisms for translating research advances into improved health care need radical review Education of all healthcare professionals and greater awareness of users' perspectives are needed in order to capitalise on the results of genomics research
If the supply of new products and services is to be rational rather than rationed, a strategic public-private partnership is essential 
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These issues will also inspire new relations between medicine and computing.
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Provision of genetic services
The current provision of genetic services in the United Kingdom has been surveyed comprehensively. [13] [14] [15] These services will be sensitive to the general drivers for change in health care 16 -particularly, the rapid advances in science and technology, the changing expectations of consumers, and the increasing financial constraints, all of which operate within the context of the agreed need to promote quality and equity of access. 17 The clinical impact will be felt by all physicians and not just the clinical geneticists, who are currently the focus for study and care of patients with single gene diseases. General practitioners will be among those most likely to confront the issues, and in some ways are the least prepared professional group. Screening for haemoglobin disorders shows what might be feasible using a multidisciplinary approach in primary care. 18 Brave New NHS?-a study by the Institute for Public Policy Research-reviews the services that could develop to fulfil the promise of research and development into genomics. 19 At present, few commercial genetic testing services are provided direct to the public. We understand the anxiety that a commercial market in testing might act to inflate demand and impose "knock on" costs for the NHS. It is therefore imperative that direct commercial provision does not grow as a result of the failure of the NHS to respond to an appropriate demand for gene diagnostic tests.
The health economy
It is also important to examine the broader economic context. By focusing on the cost of individual components of care, the NHS has no mechanism for determining whether increased spending on one component such as medicines or diagnostic tests will result in substantial savings elsewhere in the health economy or in other government funded activities. Careful consideration must be given to how the NHS can plan for the longer term. We need a holistic approach to analysing the costs of health care, and the NHS must develop its research programme so that it is aligned with policy needs. The setting up of the Public Health Genetics Unit within the Anglia and Oxford region of the NHS Executive is strategically important. 20 This unit provides a link between research, clinical practice, and NHS policy development for genetics services. The lessons learned in optimising channels of communication and in consensus building in a research setting will provide a model for developing options more widely, provided the market place is structured to incorporate the legitimate expectations of all stakeholders.
Capturing innovation
Although it is accepted that the NHS must plan an ambitious programme of quality assessment and improvement through clinical governance, the timely introduction of new and emerging medical technologies continues to pose a challenge. 21 22 If the National Institute for Clinical Excellence were developed inappropriately, for example, it could act as a barrier to delay access to new medicines and services. 23 There is still need for more penetrating analysis of the mechanisms for systematically establishing the effectiveness and appropriateness of interventions and for ensuring that these are adopted consistently.
Who sets the agenda? More research on healthcare outcomes is essential-but we need shared understanding of what evidence is required and how it is to be used. Moreover, the operational climate for innovative healthcare companies is unsettling when governments attempt to control prices or indulge in covert rationing without any parallel assessment of denied benefit. As is recognised in NHS research and development evaluations, achieving a high return on innovation-in terms of a widespread impact on clinical practice and health outcomes-requires a highly disciplined approach to priority setting, dissemination, and follow through. 24 The health services, as they are presently constructed, may become an obstacle to these objectives. 25 It is highly desirable for industry and NHS to work in partnership to share issues with the public by showing that innovation can mean better use of current resources, the replacement of obsolete practices, and measurable gains in clinical performance. Innovation need not exacerbate inequity. On the contrary, molecular medicine holds remarkable promise for improving quality of life and delivering health care more equitably.
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Education and training in genetics
The Department of Health's contribution to the House of Commons Health Committee inquiry into staffing of the NHS testifies to the future clinical value of genetics, but the implications for training have yet to be appreciated widely. 26 Urgent attention must be paid to the current, future, and continuing education of healthcare professionals if the NHS is to be used as a research resource (for example, in population genetics 27 ) and if advances in research and development are to be translated into improved health care. 28 In particular, undergraduate medical training would benefit from the inclusion of industry placements, and postgraduate training could incorporate exchange programmes with industry. The issues for training in genetics apply not 
Shaping the agenda
Without a strategy, genetic services will develop in an ad hoc manner. Services will respond to initiatives from industry, the media, or patients' demands; they may depend on idiosyncratic attitudes of health professionals or administrators; or their development may be obstructed by "cash-strapped and short sighted health purchasers." 19 The general issues for developing a strategy are probably not contentious (box). However, there is no forum in which government, the medical profession, industry, and academia can share perspectives on specific issues or resolve dissonance. The NHS has considerable possibilities for developing public and private sector partnerships in research and delivering new technical advances, and perhaps other services. However, clarity of purpose and shared commitment among stakeholders in anticipating the imagined futures are needed first. 16 This strategic partnership can become the "third way" in health care. 32 All constituents in this debate-politicians, the public, doctors, regulators, and the research community in universities and industry-will be forced to confront daunting issues on setting priorities for care, adoption of new technologies, and the rational allocation of resources. The challenges in bringing pioneer science to the heart of health care are considerable. Achieving the goals of efficiency and equity will require: increasing transparency in NHS policies on rationing, adoption of best practice clinical guidelines, increased audit of clinical performance, radical changes in medical education, and public engagement in recognising the need for greater individual responsibility in maintaining personal health. This shifting of boundaries creates new opportunities for building relevance, utility, and an integrated approach in health care. The choice is clear: will health care become increasingly rationed or rational? Rational health care is not only preferable but attainable if the difficult issues we raise receive the attention that they merit for the future clinical and political viability of the NHS.
